Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Ki-67 and p53 protein production in the development of verrucous carcinoma

View through CrossRef
Introduction. Oral verrucous carcinoma is classified as a well-differentiated squamous cell carcinoma. Histologically, it is characterized by hyperkeratosis, epithelial hyperplasia, preservation of basal membrane integrity, and chronic inflammation in the lamina propria of the mucosa. The development of verrucous carcinoma typically begins with verrucous hyperplasia, which exhibits a histological pattern similar to that of verrucous carcinoma. For a more accurate diagnosis, immunohistochemical methods are used. The proliferative activity of cells is assessed using the Ki-67 marker. Alterations in tumor cell apoptosis are studied by examining the p53 protein in its two forms: wild-type (WTp53) and mutant-type (MTp53). The paper aimed to evaluate immunoreactive cells for Ki-67 and p53 proteins in verrucous hyperplasia and verrucous carcinoma. Materials and methods. To investigate verrucous hyperplasia and verrucous carcinoma, we examined oral mucosal biopsy samples obtained from patients with a preliminary clinical diagnosis of leukoplakia. A total of 27 cases were analyzed, including 18 cases of verrucous hyperplasia (66.6%) and 9 cases of verrucous carcinoma (33.3%). Proliferative activity was assessed using anti-Ki-67 antibodies. For p53 analysis, two antibody clones were used: DO-7, which detects both wild- and mutant-type proteins, and Y5, which specifically detects the mutant form. Results. Immunoreactive cells for WTp53 protein accounted for 19.4% (16.40; 21.10) in verrucous hyperplasia compared to 26.0% (25.70; 27.10) in verrucous carcinoma, with higher nuclear staining intensity observed in the latter. For MTp53 protein, the values were 5.1% (2.90; 5.60) in verrucous hyperplasia and 28.1% (27.10; 29.90) in verrucous carcinoma. The presence of isolated immunopositive cells in the verrucous hyperplasia group may be interpreted as early genomic alterations and the onset of neoplasia. Conclusion. MTp53 protein can be used for the differential diagnosis of verrucous hyperplasia and verrucous carcinoma, as the presence of immunopositive cells indicates genomic mutations in oral mucosal epithelial cells. Keywords: verrucous carcinoma, p53, MTp53, WTp53
Title: Ki-67 and p53 protein production in the development of verrucous carcinoma
Description:
Introduction.
Oral verrucous carcinoma is classified as a well-differentiated squamous cell carcinoma.
Histologically, it is characterized by hyperkeratosis, epithelial hyperplasia, preservation of basal membrane integrity, and chronic inflammation in the lamina propria of the mucosa.
The development of verrucous carcinoma typically begins with verrucous hyperplasia, which exhibits a histological pattern similar to that of verrucous carcinoma.
For a more accurate diagnosis, immunohistochemical methods are used.
The proliferative activity of cells is assessed using the Ki-67 marker.
Alterations in tumor cell apoptosis are studied by examining the p53 protein in its two forms: wild-type (WTp53) and mutant-type (MTp53).
The paper aimed to evaluate immunoreactive cells for Ki-67 and p53 proteins in verrucous hyperplasia and verrucous carcinoma.
Materials and methods.
To investigate verrucous hyperplasia and verrucous carcinoma, we examined oral mucosal biopsy samples obtained from patients with a preliminary clinical diagnosis of leukoplakia.
A total of 27 cases were analyzed, including 18 cases of verrucous hyperplasia (66.
6%) and 9 cases of verrucous carcinoma (33.
3%).
Proliferative activity was assessed using anti-Ki-67 antibodies.
For p53 analysis, two antibody clones were used: DO-7, which detects both wild- and mutant-type proteins, and Y5, which specifically detects the mutant form.
Results.
Immunoreactive cells for WTp53 protein accounted for 19.
4% (16.
40; 21.
10) in verrucous hyperplasia compared to 26.
0% (25.
70; 27.
10) in verrucous carcinoma, with higher nuclear staining intensity observed in the latter.
For MTp53 protein, the values were 5.
1% (2.
90; 5.
60) in verrucous hyperplasia and 28.
1% (27.
10; 29.
90) in verrucous carcinoma.
The presence of isolated immunopositive cells in the verrucous hyperplasia group may be interpreted as early genomic alterations and the onset of neoplasia.
Conclusion.
MTp53 protein can be used for the differential diagnosis of verrucous hyperplasia and verrucous carcinoma, as the presence of immunopositive cells indicates genomic mutations in oral mucosal epithelial cells.
Keywords: verrucous carcinoma, p53, MTp53, WTp53.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract The tumor suppressor p53 is mutated in more than 50% of all cancers. The transcriptional activity of p53 depends on localization to the nucleus and formatio...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract p53 is the most frequently mutated gene in human cancer. As a tetrameric transcription factor, mutation of the p53 Tetramerization Domain (TD) is a mechanis...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...

Back to Top